Caboxen (Cabozantinib) 80 MG - Targeted Therapy for Advanced Cancer

Introduction: 

Caboxen (Cabozantinib) 80 MG is an advanced targeted therapy designed to treat a range of aggressive cancers. As an oral receptor tyrosine kinase inhibitor, Caboxen effectively targets and inhibits key signaling pathways involved in cancer growth and progression. This groundbreaking medication is approved for treating metastatic medullary thyroid cancer (MTC), advanced renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC) in patients who have previously received sorafenib.

Indications: Caboxen 80 MG is indicated for:

• Advanced Renal Cell Carcinoma (RCC): Caboxen is a pivotal treatment option for patients with advanced RCC, a type of cancer originating in the kidney cells.
• Advanced RCC in Combination with Nivolumab (Opdivo): For patients who are yet to receive RCC treatment, Caboxen in combination with Nivolumab provides an effective therapeutic strategy.
• Hepatocellular Carcinoma (HCC): Caboxen is approved for treating HCC, a form of liver cancer, specifically in individuals previously treated with sorafenib.
• Metastatic Medullary Thyroid Cancer (MTC): Caboxen targets a specific type of thyroid cancer that has spread to nearby tissues or other parts of the body, demonstrating resistance to previous treatment and making it unsuitable for radioactive iodine therapy.

Pharmacology: 

Caboxen works by inhibiting the activity of several crucial receptor tyrosine kinases, including MET, VEGFR-1, -2, and -3, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT-3, and TIE-2. These kinases play pivotal roles in normal cellular function and pathological processes such as tumor development, metastasis, angiogenesis, drug resistance, and maintenance of the tumor microenvironment.

Dosage & Administration: 

For effective treatment outcomes, adhere to the following guidelines:

• Recommended Dosage for Renal Cell Carcinoma: Take 80 mg of Caboxen once daily on an empty stomach. Continue until clinical benefit is no longer observed or unacceptable toxicity occurs.
• Recommended Dosage for Hepatocellular Carcinoma: Take 80 mg of Caboxen daily without food until disease progression or intolerable side effects occur. Follow physician instructions closely.
• Thyroid Cancer Dosage: For adults and children aged 12 and above, Caboxen is the solution for treating thyroid cancer that has spread and is unresponsive to previous treatments. Follow medical guidance closely.

Important Administration Instructions:

• Take Caboxen at least 1 hour before or 2 hours after eating.
• Swallow the tablets whole; do not crush.
• In case of a missed dose, avoid taking it within 12 hours of the next dose.
• Adjust the dosage for patients with hepatic impairment or those taking strong CYP450 inducers/inhibitors.
• Discontinue Caboxen 28 days before scheduled surgery, including dental procedures.

Interactions:

• Avoid Strong CYP3A4 Inhibitors: Combining Caboxen with potent CYP3A4 inhibitors may increase the risk of side effects. Adjust dosage or avoid coadministration as recommended.
• Be Cautious with Strong CYP3A Inducers: Coordinating Caboxen with strong CYP3A4 inducers could impact effectiveness. Adjust dosage accordingly.
• Grapefruit Alert: Steer clear of grapefruit or grapefruit juice, as they can influence Caboxen exposure.
• St. John’s Wort Caution: Be cautious with St. John’s Wort, as it can decrease Caboxen exposure.

For the most effective and safe use of Caboxen 80 MG, always consult a registered physician before starting treatment or making any adjustments. Caboxen represents a significant advancement in cancer therapy, providing hope and progress for patients facing these aggressive forms of cancer.